



## Breadcrumb

1. [Home](#)

## Entity Print



Selim Corbacioglu  
PDWP Chair  
Germany

## Major achievements

In 2021, a major focus of the WP activities was the challenge to offer an educational program adapted to the circumstances of the COVID crisis. The mandatory virtual format encouraged the PDWP to implement a monthly e-learning session into its educational portfolio. This allowed us to invite attendees from all over the world

beyond the usual EBMT catchment area. Offering updates on contemporary and burning topics of the entire transplant field. The result was extremely successful. Many sessions were followed by more than 100 attendees from all over the world.

“How to transplant patients with Sickle Cell Disease/Thalassemia in 2021”, “Virus-specific T-cells in 2021” and “How to diagnose and treat VOD in 2021” are only some exemplary topics that were offered via a pre-recorded webinar and consecutively discussed in a moderated 45 min live session.

The highest rate of attendance with 249 was achieved with ‘How to treat acute Graft-versus-Host Disease in 2021’, hosted by Anita Lawitschka and Hilde Greinix.

Most recently, a half-day webinar on “Challenges in CAR T-cell therapy for paediatric ALL”, organized and with active contribution from the Cellular Therapies Subcommittee, has been realized with great success. (See complete list of talks below).

From October 7<sup>th</sup> to 9<sup>th</sup> the first international Educational Course on Cancer Predisposition was hosted by the WP, also in a fully virtual format. During the three-days meeting, all aspects of the current cancer predisposition syndromes were presented by more than 30 international experts worldwide. Each session offered the opportunity to interact directly with the speakers in order to discuss and ask questions. The meeting was attended by 84 participants from 24 countries.

The scientific output in 2021 reached an IF of 60.72. One of the most important publications of this year are the results of the outcomes of unmanipulated haploidentical transplantation using post-transplant cyclophosphamide (PT-Cy) in pediatric patients with Acute Lymphoblastic Leukemia from Annalisa Ruggeri, published in Transplant Cell Therapy.

Another highlight was the meta-analysis on efficacy of allogeneic hematopoietic cell transplantation in Sickle Cell Disease, as a joint publication of the EBMT PDWP and the Sickle Cell Transplantation International Consortium.

The Educational Program for 2022 foresees the continuation of the very successful E-learning sessions with expert presentations and live Q&A sessions. Depending on the topic, some will be realized in a provocative pro’s and con’s format.

Moreover, the long-standing tradition of the very popular biannual “Sickle Cell Disease Meeting will be (hopefully) realized as a face-to-face meeting” in the city of Regensburg, Germany. Due to the overlapping interests the focus will be extended,

including thalassemia syndromes. Therefore, save the date for this flagship PDWP educational event for May 19<sup>th</sup> to 21<sup>st</sup>, 2022.

## Principal research studies

[The impact of pre-transplant extramedullary disease on the outcome of allogeneic hematopoietic cell transplantation for Acute Myeloid Leukemia in Children- A combined CIBMTR and EBMT analysis](#)

[Study type](#)

[Retrospective Studies](#)

[Diseases](#)

[Acute Myeloid Leukaemia \(AML\)](#)

[Group](#)

[Paediatric Diseases Working Party \(PDWP\)](#)

[Type of treatment](#)

[Allogeneic](#)

[Principal investigator](#)

[Kanchan Rao](#)

[Late effects after hematopoietic stem cell transplantation in patients with HLH](#)

[Study type](#)

[Retrospective Studies](#)

[Diseases](#)

[Other non-malignant disorders](#)

[Group](#)

[Paediatric Diseases Working Party \(PDWP\)](#)

[Inborn Errors Working Party \(IEWP\)](#)

[Transplant Complications Working Party \(TCWP\)](#)

[Type of treatment](#)

-

[Principal investigator](#)

[AnnaCarin Horne](#)

[H SCT for Congenital Amegakaryocytic thrombopecytopenia \(CAMT\)](#)

[Study type](#)

[Closed Survey/Study](#)

[Diseases](#)

[Bone marrow failure](#)

[Group](#)

[Paediatric Diseases Working Party \(PDWP\)](#)

[Type of treatment](#)

[Allogeneic](#)

[Principal investigator](#)

[Clémence Aldebert](#)

[Allogeneic hematopoietic stem cell transplantation for the BCR-ABL1 negative myeloproliferative neoplasms in children](#)

[Study type](#)

[Retrospective Studies](#)

[Diseases](#)

[Myeloproliferative Neoplasm \(MPN\)](#)

[Group](#)

[Paediatric Diseases Working Party \(PDWP\)](#)

[Type of treatment](#)

[Allogeneic](#)

[Principal investigator](#)

[Jacek Wachowiak](#)

## **Key publications**

[2021](#)

[Outcomes of Unmanipulated Haploidentical Transplantation Using Post-Transplant Cyclophosphamide \(PT-Cy\) in Pediatric Patients With Acute Lymphoblastic Leukemia](#)

[Group](#)

[Paediatric Diseases Working Party \(PDWP\)](#)

[1st listed author](#)

[Annalisa Ruggeri](#)

[Journal](#)

[Transplant Cell Ther.](#)

[2021](#)

[Supportive Care During Pediatric Hematopoietic Stem Cell Transplantation: Prevention of Infections. A Report From Workshops on Supportive Care of the Paediatric Diseases Working Party \(PDWP\) of the European Society for Blood and Marrow Transplantation \(EBMT\)](#)

[Group](#)

[Paediatric Diseases Working Party \(PDWP\)](#)

[Nursing Paediatric Committee](#)

[1st listed author](#)

[Marianne Ifversen](#)

[Journal](#)

[Front. Pediatr.](#)

[2021](#)

[Specialized Pediatric Palliative Care Services in Pediatric Hematopoietic Stem Cell Transplant Centers](#)

[Group](#)

[Paediatric Diseases Working Party \(PDWP\)](#)

[Nursing Paediatric Committee](#)

[1st listed author](#)

[Hilda Mekelenkamp](#)

[Journal](#)

[MDPI children](#)

[2021](#)

[Pregnancy and pregnancy outcomes after hematopoietic stem cell transplantation in childhood: a cross-sectional survey of the EBMT Pediatric Diseases Working Party](#)

[Group](#)

[Paediatric Diseases Working Party \(PDWP\)](#)

[1st listed author](#)

[T Diesch-Furlanetto](#)

[Journal](#)

[Hum Reprod.](#)

[2021](#)

[Systematic Review/Meta-Analysis on Efficacy of Allogeneic Hematopoietic Cell Transplantation in Sickle Cell Disease: An International Effort on Behalf of the Pediatric Diseases Working Party of European Society for Blood and Marrow Transplantation and the Sickle Cell Transplantation International Consortium](#)

[Group](#)

[Paediatric Diseases Working Party \(PDWP\)](#)

[Other society](#)

[1st listed author](#)

[Madiha Iqbal](#)


[Journal](#)

[Transplant Cell Ther.](#)

[See the full list of the PDWP 2021 publications](#)



Impact factor  
(Paediatric Diseases)



**2019 2020 2021**

<b>Oral presentations</b>	<b>8</b>	<b>8</b>	<b>1</b>
<b>Poster presentations</b>	<b>1</b>	<b>3</b>	<b>1</b>
<b>Educational events</b>	<b>1</b>	<b>1</b>	<b>1</b>

**Major educational events**



[Event](#)

## [\*\*Paediatric Diseases Working Party Educational Course on Cancer Predisposition\*\*](#)

[Oct 07, 2021 - Oct 09, 2021 / VIRTUAL MEETING](#)

[Discover more](#)

## **Webinars and e-courses**

[How to transplant patients with Sickle Cell disease in 2021](#)

[Hormonal replacement therapy in iatrogenic gonadal insufficiency after HSCT: practical recommendations](#)

[How to treat chronic Graft-versus-Host Disease in 2021](#)

[How to treat acute Graft-versus-Host Disease in 2021](#)

[Adoptive transfer of virus-specific T-cells \(VST\)](#)

[How to transplant patients with Thalassemia in 2021?](#)

[How to diagnose and treat Venous-occlusive Disease in 2021?](#)

[Challenges in CAR T cell therapy for Paediatric ALL.](#)